Intellia Therapeutics, Inc. 8-K

What Happened
Intellia Therapeutics announced it completed a public offering of 16,744,187 shares of common stock at $10.75 per share under an underwriting agreement dated April 28, 2026 with Jefferies, Goldman Sachs and Citigroup. The underwriters’ 30‑day option to purchase an additional 2,511,628 shares was exercised in full on April 29, 2026, and the Offering closed on April 30, 2026. Intellia estimates net proceeds after fees and expenses of approximately $194.6 million. The company said it will use the proceeds to advance clinical development and prepare for commercial launch of lead programs, fund R&D for other pipeline candidates, pursue potential acquisitions, and for working capital and general corporate purposes.

Key Details

• Offered 16,744,187 shares at $10.75 per share; 30‑day over‑allotment of 2,511,628 shares was fully exercised.
• Estimated net proceeds: ~ $194.6 million.
• Preliminary cash, cash equivalents and marketable securities as of March 31, 2026: ~$517.2 million (unaudited).
• Intellia raised ~$33.6 million net from its "at the market" equity program in Q1 2026. Company expects the combined cash resources to fund operations at least into 2028 under current plans (excludes potential product revenue, milestone payments, or other strategic uses).

Why It Matters
The offering materially increases Intellia’s cash position and extends its runway, supporting ongoing clinical programs and potential commercial launch activities (including planning around lonvoguran ziclumeran) as well as R&D and possible acquisitions. Retail investors should note the company’s preliminary cash figure is unaudited and the stated runway excludes potential future product revenues or collaboration milestones, which could materially affect the company’s financial outlook.